Table 6.
Means ± SD of anti-Dsg1/3 values in patients with pemphigus vulgaris 3 months after rituximab therapy (based on clinical response)
| Total anti-Dsg1 (U/ml) | Pathogenic anti-Dsg1 (U/ml) | Nonpathogenic anti-Dsg1 (U/ml) | Total anti-Dsg3 (U/ml) | Pathogenic anti-Dsg3 (U/ml) | Nonpathogenic anti-Dsg3 (U/ml) | |
|---|---|---|---|---|---|---|
| CR (n = 37) | 7.67 ± 22.41 | 6.07 ± 22.29 | 1.60 ± 2.84 | 50.80 ± 69.00 | 46.92 ± 63.61 | 3.88 ± 7.63 |
| PR (n = 30) | 11.97 ± 34.01 | 10.58 ± 32.80 | 1.39 ± 1.23 | 71.83 ± 82.45 | 68.21 ± 79.58 | 3.62 ± 4.56 |
| NR (n = 8) | 64.03 ± 92.64 | 61.99 ± 90.97 | 2.04 ± 1.79 | 127.49 ± 72.38 | 121.41 ± 68.43 | 6.08 ± 6.03 |
| p-value⁎ | .002 | .002 | .756 | .035 | .028 | .621 |
CR, complete remission; Dsg, desmoglein; PR, partial remission; NR, nonresponding; SD, standard deviation
⁎
One-way analysis of variance test.